|   From the Trenches

Collaborating with Patient Advocacy Groups to Advance Rare Disease Awareness and Support

Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives credibly and meaningfully, we must raise awareness about the conditions we are attempting to treat. One of the most effective ways is to engage with patient advocacy groups who are more closely connected to patients and caregivers and have a deep knowledge of their needs. Access to patient groups is particularly important for work related to rare disease indications given the challenging combination of urgent patient needs, and limited resources and knowledge.

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   LifeSciVC

In Defense Of Early Stage Biotech IPOs

By Bruce Booth, DPhil, Partner

There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market.

Read more.


  |   LifeSciVC

Innovation Ecosystem: A Year Of Risk-Off Correlations

By Bruce Booth, DPhil, Partner

Misery loves company, and so it goes with the stock market for the innovation ecosystem these days.

Read more.


  |   LifeSciVC

Biotech Bears: Jumping A Lower Bar Or A Higher One?

By Bruce Booth, DPhil, Partner

Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what caused the carnage.

Read more.


  |   From the Trenches

A Virtual Company In A Virtual World

In December 2019, I was in London meeting with my future co-founders to discuss an asset that would eventually become the cornerstone of a virtual drug development company. At that time, Kinaset Therapeutics, Inc. as it would become, had negotiated terms to in-license an asset from a UK based company that was changing its strategy. With terms agreed and a period of exclusivity in hand, the plan was to launch a private fundraising on the heels of JP Morgan in January 2020.

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.